PART I Overview We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&I") space. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We aim to achieve this by developing truly transformational and highly disease-specific immunotherapies. We are prioritizing the development of a pipeline for I&I indications e...
Q2 FY2026 — expected 2026-09-12
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | BRNS | discussed_in_filing Artificial Intelligence | |
| topic_mention | BRNS | discussed_in_filing Cybersecurity | |
| topic_mention | BRNS | discussed_in_filing Trusted Computing | |
| topic_mention | BRNS | discussed_in_filing Blockchain & Crypto | |
| topic_mention | BRNS | discussed_in_filing Regulation | |
| topic_mention | BRNS | discussed_in_filing Enterprise | |
| topic_mention | BRNS | discussed_in_filing Healthcare & Bio | |
| topic_mention | BRNS | discussed_in_filing Platform & Ecosystem | |
| topic_mention | BRNS | discussed_in_filing Artificial Intelligence | |
| topic_mention | BRNS | discussed_in_filing Cybersecurity | |
| topic_mention | BRNS | discussed_in_filing Trusted Computing | |
| topic_mention | BRNS | discussed_in_filing Blockchain & Crypto | |
| topic_mention | BRNS | discussed_in_filing Regulation | |
| topic_mention | BRNS | discussed_in_filing Enterprise | |
| topic_mention | BRNS | discussed_in_filing Healthcare & Bio | |
| topic_mention | BRNS | discussed_in_filing Platform & Ecosystem | |
| topic_mention | BRNS | discussed_in_filing Artificial Intelligence | |
| topic_mention | BRNS | discussed_in_filing Cybersecurity | |
| topic_mention | BRNS | discussed_in_filing Trusted Computing | |
| topic_mention | BRNS | discussed_in_filing Blockchain & Crypto |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001828185-26-000012 | EDGAR | 119K words |
| 2025-03-20 | 2024-12-31 | 0001828185-25-000021 | EDGAR | — |
| 2024-03-20 | 2023-12-31 | 0001828185-24-000011 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0001104659-23-036275 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001104659-22-037794 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001828185-25-000072 | EDGAR | 29K words |
| 2025-08-07 | 2025-06-30 | 0001828185-25-000059 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001828185-25-000037 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001828185-24-000085 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001828185-24-000075 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001828185-24-000036 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001410578-23-002303 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001410578-23-001666 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001104659-23-059430 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001104659-22-117255 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001104659-22-087945 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001104659-22-058820 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001104659-26-037698 | EDGAR | 1K words |
| 2026-03-13 | 0001828185-26-000011 | EDGAR | — |
| 2026-02-23 | 0001104659-26-018283 | EDGAR | — |
| 2026-01-06 | 0001828185-26-000004 | EDGAR | — |
| 2025-12-10 | 0001828185-25-000075 | EDGAR | — |
| 2025-11-07 | 0001828185-25-000071 | EDGAR | — |
| 2025-09-30 | 0001104659-25-094754 | EDGAR | — |
| 2025-08-07 | 0001828185-25-000058 | EDGAR | — |
| 2025-06-10 | 0001104659-25-058141 | EDGAR | — |
| 2025-05-07 | 0001828185-25-000036 | EDGAR | — |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001828185 |
| Ticker | BRNS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report